SlideShare una empresa de Scribd logo
1 de 2
Descargar para leer sin conexión
Press Release
Theralase Launches New Head Office and Therapeutic Laser Centre
Toronto, ON – May 28, 2013 - Theralase Technologies Inc. (TSX-V: TLT), announced today the launch of
its new head office and multidisciplinary therapeutic laser centre in the heart of the Beach District of
Toronto, Ontario. The new laser centre will provide local patients with a proven, highly effective, non-
invasive treatment to address painful and inflamed medical conditions, without the need for surgery or
pharmaceutical drugs, and their associated side effects.
“The Centre will be a multidisciplinary pain and rehabilitation treatment centre focused on delivering
Theralase therapeutic laser therapy treatments through mainstream medical practitioners, such as:
medical doctors, chiropractors, physical therapists, naturopathic doctors, doctors of podiatry and
registered massage therapists,” said Dr. Rhonda Mostyn, Clinic Director of Theralase Therapeutic Laser
Centre. “Our initial focus will be primarily chronic and acute pain caused by neural muscular skeletal
conditions, sports injuries, motor vehicle accidents or trauma, but as the centre grows, we may branch
out into other disciplines such as wound healing and addiction.”
“With regards to our growing number of customers, the new training facility will provide state of the
art conferencing technology and training sessions on our cutting-edge technology, laser therapy
certification courses and the latest treatment protocol optimization support,” said Roger Dumoulin
White, President and CEO of Theralase Technologies. “The new corporate head office, in addition to
housing executive management, finance, sales and marketing functions will also support an ISO-13485
certified, Health Canada, FDA and CE approved facility to manufacture the Theralase line of therapeutic
lasers, as well as aftermarket sales and service support for all of Theralase’s healthcare customers.
Thousands of satisfied healthcare practitioners and patients throughout North America attest to the
safety and effectiveness of Theralase’s laser technology. We expect the laser centre to be very
successful in the near term adding a significant revenue stream to the Company.”
The corporate head office and therapeutic laser centre will now be located at, 1945 Queen Street East,
Toronto, Ontario, Canada, M4L 1H7, Phone: 416-699-LASE (5273), Toll-free: 1-866-843-LASE (5273),
Fax: 416-699-5250, and will be open from 7:00 am to 7:00 pm 7 days a week to fully service our local
patients and our international sales team.
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro
musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo
Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when
light activated by Theralase’s proprietary and patented laser technology.
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting
www.sedar.com.
Press Release
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 242
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com

Más contenido relacionado

Más de Theralase Technologies Inc.

Theralase Expands Board of Directors with Strong Financing Capabilities
Theralase Expands Board of Directors with Strong Financing CapabilitiesTheralase Expands Board of Directors with Strong Financing Capabilities
Theralase Expands Board of Directors with Strong Financing CapabilitiesTheralase Technologies Inc.
 
Efficacy of super pulsed 905 nm low level laser therapy in the management of ...
Efficacy of super pulsed 905 nm low level laser therapy in the management of ...Efficacy of super pulsed 905 nm low level laser therapy in the management of ...
Efficacy of super pulsed 905 nm low level laser therapy in the management of ...Theralase Technologies Inc.
 
Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...
Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...
Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...Theralase Technologies Inc.
 
Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...Theralase Technologies Inc.
 
Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...Theralase Technologies Inc.
 
The Science of Laser Therapy and Clinical Applications
The Science of Laser Therapy and Clinical Applications The Science of Laser Therapy and Clinical Applications
The Science of Laser Therapy and Clinical Applications Theralase Technologies Inc.
 

Más de Theralase Technologies Inc. (20)

2012 Year End Results
2012 Year End Results2012 Year End Results
2012 Year End Results
 
Theralase's unique value proposition
Theralase's unique value propositionTheralase's unique value proposition
Theralase's unique value proposition
 
Theralase Expands Board of Directors with Strong Financing Capabilities
Theralase Expands Board of Directors with Strong Financing CapabilitiesTheralase Expands Board of Directors with Strong Financing Capabilities
Theralase Expands Board of Directors with Strong Financing Capabilities
 
The Science of Therapeutic Laser Technology
The Science of Therapeutic Laser TechnologyThe Science of Therapeutic Laser Technology
The Science of Therapeutic Laser Technology
 
Efficacy of super pulsed 905 nm low level laser therapy in the management of ...
Efficacy of super pulsed 905 nm low level laser therapy in the management of ...Efficacy of super pulsed 905 nm low level laser therapy in the management of ...
Efficacy of super pulsed 905 nm low level laser therapy in the management of ...
 
Cold Laser Therapy - Companion book
Cold Laser Therapy - Companion bookCold Laser Therapy - Companion book
Cold Laser Therapy - Companion book
 
Equine Book _Therapeutic Laser
Equine Book _Therapeutic LaserEquine Book _Therapeutic Laser
Equine Book _Therapeutic Laser
 
Cold Laser Therapy - The Human Book
Cold Laser Therapy - The Human BookCold Laser Therapy - The Human Book
Cold Laser Therapy - The Human Book
 
Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...
Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...
Efficacy of super pulsed 905 nm low level laser therapy (lllt) in the managem...
 
Theralase Compounds Destroy Bladder Cancer
Theralase Compounds Destroy Bladder CancerTheralase Compounds Destroy Bladder Cancer
Theralase Compounds Destroy Bladder Cancer
 
Theralase Photodynamic Compounds Destroy Cancer
Theralase Photodynamic Compounds Destroy CancerTheralase Photodynamic Compounds Destroy Cancer
Theralase Photodynamic Compounds Destroy Cancer
 
Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...
 
Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...Theralase photo dynamic compounds effective in destruction of drug resistant ...
Theralase photo dynamic compounds effective in destruction of drug resistant ...
 
Meta analysis of pain relief effects with laser
Meta analysis of pain relief effects with laserMeta analysis of pain relief effects with laser
Meta analysis of pain relief effects with laser
 
Theralase commences equity financing oct 2012
Theralase commences equity financing oct 2012Theralase commences equity financing oct 2012
Theralase commences equity financing oct 2012
 
Theralase expands into china rw - 10 01 2012
Theralase expands into china   rw - 10 01 2012Theralase expands into china   rw - 10 01 2012
Theralase expands into china rw - 10 01 2012
 
Osteoarthritis clinical trial
Osteoarthritis clinical trialOsteoarthritis clinical trial
Osteoarthritis clinical trial
 
Newsletter comp
Newsletter compNewsletter comp
Newsletter comp
 
The Science of Laser Therapy and Clinical Applications
The Science of Laser Therapy and Clinical Applications The Science of Laser Therapy and Clinical Applications
The Science of Laser Therapy and Clinical Applications
 
2011 year end_results_ver_4
2011 year end_results_ver_42011 year end_results_ver_4
2011 year end_results_ver_4
 

Último

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 

Último (20)

Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 

Theralase Launches New Head Office and Therapeutic Laser Centre

  • 1. Press Release Theralase Launches New Head Office and Therapeutic Laser Centre Toronto, ON – May 28, 2013 - Theralase Technologies Inc. (TSX-V: TLT), announced today the launch of its new head office and multidisciplinary therapeutic laser centre in the heart of the Beach District of Toronto, Ontario. The new laser centre will provide local patients with a proven, highly effective, non- invasive treatment to address painful and inflamed medical conditions, without the need for surgery or pharmaceutical drugs, and their associated side effects. “The Centre will be a multidisciplinary pain and rehabilitation treatment centre focused on delivering Theralase therapeutic laser therapy treatments through mainstream medical practitioners, such as: medical doctors, chiropractors, physical therapists, naturopathic doctors, doctors of podiatry and registered massage therapists,” said Dr. Rhonda Mostyn, Clinic Director of Theralase Therapeutic Laser Centre. “Our initial focus will be primarily chronic and acute pain caused by neural muscular skeletal conditions, sports injuries, motor vehicle accidents or trauma, but as the centre grows, we may branch out into other disciplines such as wound healing and addiction.” “With regards to our growing number of customers, the new training facility will provide state of the art conferencing technology and training sessions on our cutting-edge technology, laser therapy certification courses and the latest treatment protocol optimization support,” said Roger Dumoulin White, President and CEO of Theralase Technologies. “The new corporate head office, in addition to housing executive management, finance, sales and marketing functions will also support an ISO-13485 certified, Health Canada, FDA and CE approved facility to manufacture the Theralase line of therapeutic lasers, as well as aftermarket sales and service support for all of Theralase’s healthcare customers. Thousands of satisfied healthcare practitioners and patients throughout North America attest to the safety and effectiveness of Theralase’s laser technology. We expect the laser centre to be very successful in the near term adding a significant revenue stream to the Company.” The corporate head office and therapeutic laser centre will now be located at, 1945 Queen Street East, Toronto, Ontario, Canada, M4L 1H7, Phone: 416-699-LASE (5273), Toll-free: 1-866-843-LASE (5273), Fax: 416-699-5250, and will be open from 7:00 am to 7:00 pm 7 days a week to fully service our local patients and our international sales team. About Theralase Technologies Inc.: Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology. For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
  • 2. Press Release This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release. For More Information: Roger Dumoulin-White President & CEO 416-699-LASE (5273) ext. 225 rwhite@theralase.com Kristina Hachey Chief Financial Officer 416-699-LASE (5273) ext. 224 khachey@theralase.com Arkady Mandel Chief Scientific Officer 416-699-LASE (5273) ext. 242 amandel@theralase.com Greg Bewsh Director of Investor Relations 416-699-LASE (5273) ext. 258 gbewsh@theralase.com